Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment.

Chao-Yi Wu, Ashley C Kupferschmid, Liu Chen, Alison J McManus, Pia Kivisäkk, Jake A Galler, Nadine A Schwab, Libby A DesRuisseaux, Victoria J Williams, Jessica Gerber, Misha Riley, Cathrine Young, Edmarie Guzmán-Vélez, Hiroko H Dodge, Rudolph E Tanzi, Clifford M Singer, Steven E Arnold

Neurology Massachusetts General Hospital Harvard Medical School Boston USA.Neurology Massachusetts General Hospital Harvard Medical School Boston USA. · pubmed

Paper

Abstract

Age-associated depletion in nicotinamide adenine dinucleotide (NAD+) concentrations has been implicated in metabolic, cardiovascular, and neurodegenerative disorders. Supplementation with NAD+ precursors, such as nicotinamide riboside (NR), offers a potential therapeutic avenue against neurodegenerative pathologies in aging, Alzheimer's disease, and related dementias. A crossover, double-blind, randomized placebo (PBO) controlled trial was conducted to test the safety and efficacy of 8 weeks' active treatment with NR (1 g/day) on cognition and plasma AD biomarkers in older adults with subjective cognitive decline and mild cognitive impairment.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the effects of nicotinamide riboside (NR) supplementation on cognitive decline, which is associated with aging and neurodegenerative diseases. While it addresses a potential therapeutic approach to mitigate cognitive decline, it primarily focuses on symptomatic treatment rather than addressing the root causes of aging. The findings may contribute to the understanding of NAD+ precursors in cognitive health, but the impact is limited as it does not significantly advance the fundamental understanding of aging mechanisms.

Author of this paper? Send a correction.